{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:51:06Z","timestamp":1785408666776,"version":"3.56.0"},"reference-count":74,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respir Res Clin Pract"],"DOI":"10.36416\/1806-3756\/e20260324","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:54:10Z","timestamp":1782935650000},"page":"e20260324","source":"Crossref","is-referenced-by-count":0,"title":["Linezolid in the era of bedaquilinepretomanid- linezolid-based regimens: an indispensable challenge"],"prefix":"10.36416","author":[{"given":"Ana Paula","family":"Santos","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0198v2949","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade do Estado do Rio de Janeiro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Carvalho de Queiroz Mello","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03490as77","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal do Rio de Janeiro"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref0","unstructured":"1. World Health Organization. Guidelines for the Programmatic"},{"key":"ref1","unstructured":"Management of Drug-Resistant Tuberculosis: 2011 Update. Geneva:"},{"key":"ref2","unstructured":"World Health Organization; 2011."},{"key":"ref3","unstructured":"2. World Health Organization. Rapid communication: key changes to"},{"key":"ref4","unstructured":"treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/"},{"key":"ref5","unstructured":"RR-TB). Available from: www.who.int\/tb\/publications\/2018\/rapid_"},{"key":"ref6","unstructured":"communications_MDR\/en\/ 2018"},{"key":"ref7","unstructured":"3. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF,"},{"key":"ref8","unstructured":"Baghaei P, et al. Treatment correlates of successful outcomes in"},{"key":"ref9","unstructured":"pulmonary multidrug-resistant tuberculosis: an individual patient"},{"key":"ref10","unstructured":"data meta-analysis. Lancet. 2018;392(10150):821-834. https:\/\/doi."},{"key":"ref11","unstructured":"org\/10.1016\/S0140-6736(18)31644-1"},{"key":"ref12","unstructured":"4. World Health Organization. WHO consolidated guidelines on"},{"key":"ref13","unstructured":"tuberculosis. Module 4: treatment and care. Geneva: World Health"},{"key":"ref14","unstructured":"Organization; 2025."},{"key":"ref15","unstructured":"5. Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of"},{"key":"ref16","unstructured":"several novel oxazolidinones against Mycobacterium tuberculosis in"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"a murine model. Antimicrob Agents Chemother. 1999;43(5):1189-91.","DOI":"10.1128\/AAC.43.5.1189"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1128\/AAC.43.5.1189","DOI":"10.1128\/AAC.43.5.1189"},{"key":"ref19","unstructured":"6. Barry PJ, O\u2019Connor TM. Novel agents in the management"},{"key":"ref20","unstructured":"of Mycobacterium tuberculosis disease. Curr Med Chem."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"2007;14(18):2000-8. https:\/\/doi.org\/10.2174\/092986707781368496","DOI":"10.2174\/092986707781368496"},{"key":"ref22","unstructured":"7. Amiri M, Cheraghi M, Ghafari N, Nasiri MJ, Silva DR, D\u2019Ambrosio"},{"key":"ref23","unstructured":"L, et al. Safety and tolerability of linezolid to treat tuberculosis:"},{"key":"ref24","unstructured":"a systematic review and meta-analysis. Respir Res Clin Pract"},{"key":"ref25","unstructured":"2026;52(3):e20250464."},{"key":"ref26","unstructured":"8. Kodama T, Sasaki Y, Tsuyuguchi K, Okumura M, Kamada K, Yamane"},{"key":"ref27","unstructured":"A, et al. Clinical outcomes of linezolid-related adverse events"},{"key":"ref28","unstructured":"in patients with multidrug-resistant TB. Int J Tuberc Lung Dis."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"2025;29(10):462-468. https:\/\/doi.org\/10.5588\/ijtld.25.0125","DOI":"10.5588\/ijtld.25.0125"},{"key":"ref30","unstructured":"9. Munandar MAR, Machfudz A, Munandar HP, Herlina L. Peripheral"},{"key":"ref31","unstructured":"Neuropathy Associated with Linezolid Dosage in MDR-TB: A"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Systematic Review. Int J Med Sci Health Res. 2026;25:27-86. https:\/\/","DOI":"10.70070\/8fm3z016"},{"key":"ref33","unstructured":"doi.org\/10.70070\/8fm3z016"},{"key":"ref34","unstructured":"10. Cheng J, Yuan Y, Li J, Zhang R, Fan X, Xu Z, et al. Therapeutic Drug"},{"key":"ref35","unstructured":"Monitoring of Linezolid in Drug-Resistant Tuberculosis Patients:"},{"key":"ref36","unstructured":"Clinical Factors and Hematological Toxicities. Infect Drug Resist."},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"2024;17:2531-2540. https:\/\/doi.org\/10.2147\/IDR.S464429","DOI":"10.2147\/IDR.S464429"},{"key":"ref38","unstructured":"11. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L,"},{"key":"ref39","unstructured":"Ngubane N, et al. Bedaquiline-Pretomanid-Linezolid Regimens for"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810-823.","DOI":"10.1056\/NEJMoa2119430"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2119430","DOI":"10.1056\/NEJMoa2119430"},{"key":"ref42","unstructured":"12. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM,"},{"key":"ref43","unstructured":"et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"N Engl J Med. 2020;382(10):893-902. https:\/\/doi.org\/10.1056\/","DOI":"10.1056\/NEJMoa1901814"},{"key":"ref45","unstructured":"NEJMoa1901814"},{"key":"ref46","unstructured":"13. Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et"},{"key":"ref47","unstructured":"al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"N Engl J Med. 2022;387(25):2331-2343. https:\/\/doi.org\/10.1056\/","DOI":"10.1056\/NEJMoa2117166"},{"key":"ref49","unstructured":"NEJMoa2117166"},{"key":"ref50","unstructured":"14. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade\/"},{"key":"ref51","unstructured":"Departamento de Doen\u00e7as Cr\u00f4nicas e Infec\u00e7\u00f5es Sexualmente"},{"key":"ref52","unstructured":"Transmiss\u00edveis\/Coordena\u00e7\u00e3o Geral de Vigil\u00e2ncia das Doen\u00e7as de"},{"key":"ref53","unstructured":"Transmiss\u00e3o Respirat\u00f3ria de Condi\u00e7\u00f5es Cr\u00f4nicas. Nota Informativa"},{"key":"ref54","unstructured":"N\u00ba 9\/2021-CGDR\/DCCI\/SVS\/MS."},{"key":"ref55","unstructured":"15. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade\/"},{"key":"ref56","unstructured":"Departamento de Doen\u00e7as Cr\u00f4nicas e Infec\u00e7\u00f5es Sexualmente"},{"key":"ref57","unstructured":"Transmiss\u00edveis\/Coordena\u00e7\u00e3o Geral de Vigil\u00e2ncia das Doen\u00e7as de"},{"key":"ref58","unstructured":"Transmiss\u00e3o Respirat\u00f3ria de Condi\u00e7\u00f5es Cr\u00f4nicas. Nota Informativa"},{"key":"ref59","unstructured":"N\u00ba 1\/2025-CGDR\/DCCI\/SVS\/MS."},{"key":"ref60","unstructured":"16. Chen RH, Burke A, Cho JG, Alffenaar JW, Davies Forsman L. New"},{"key":"ref61","unstructured":"Oxazolidinones for Tuberculosis: Are Novel Treatments on the"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Horizon? Pharmaceutics. 2024;16(6):818. https:\/\/doi.org\/10.3390\/","DOI":"10.3390\/pharmaceutics16060818"},{"key":"ref63","unstructured":"pharmaceutics16060818"},{"key":"ref64","unstructured":"17. Heinrich N, Manyama C, Koele SE, Mpagama S, Mhimbira F, Sebe"},{"key":"ref65","unstructured":"M, et al. Sutezolid in combination with bedaquiline, delamanid, and"},{"key":"ref66","unstructured":"moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01):"},{"key":"ref67","unstructured":"a prospective, open-label, randomised, phase 2b dose-finding trial."},{"key":"ref68","unstructured":"Lancet Infect Dis. 2025;25(11):1208-1218. https:\/\/doi.org\/10.1016\/"},{"key":"ref69","unstructured":"S1473-3099(25)00213-0"},{"key":"ref70","unstructured":"18. Lombardi A, Pappas F, Bruinenberg P, Nedelman J, Taneja R,"},{"key":"ref71","unstructured":"Hickman D, et al. Pharmacokinetics, tolerability, and safety of TBI223, a novel oxazolidinone, in healthy participants. Antimicrob"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Agents Chemother. 2025;69(4):e0154224. https:\/\/doi.org\/10.1128\/","DOI":"10.1128\/aac.00562-25"},{"key":"ref73","unstructured":"aac.01542-24"}],"container-title":["Respiratory Research &amp; Clinical Practice"],"original-title":[],"link":[{"URL":"https:\/\/www.ithenticate.com\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:55:53Z","timestamp":1782935753000},"score":1,"resource":{"primary":{"URL":"https:\/\/rrcpjournal.org\/article\/linezolid-in-the-era-of-bedaquilinepretomanid-linezolid-based-regimens-an-indispensable-challenge\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":74,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20260324","relation":{},"ISSN":["3086-3910"],"issn-type":[{"value":"3086-3910","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"2026-0324"}}